John Gillen
CEO & Director
For the past two decades John Gillen has dedicated his life to exploring the latest NAD+ (Nicotinamide Adenine Dinucleotide) therapies, delivering cutting-edge treatments to the UK and across Europe.
Learn MoreMeet the team behind our company's success! Our team consists of highly skilled professionals who are passionate about delivering exceptional results. We have diverse backgrounds and expertise in various fields, which allows us to approach problems from different perspectives.
The driving force behind our company's vision and mission
Our staff member at Eulas
Discover the ways in which psychedelic therapy can help in treating depression and anxiety. Read more
Discover more about a new clinical trial underway in the UK that explores the effectiveness of using ketamine to treat serious alcohol addictions. Read more
While traditional talk therapy can be effective for many people, there is growing interest in exploring alternative forms of therapy that involve the use of mind-altering substances. Two such substances that are currently being explored for their therapeutic potential are MDMA and Ketamine. Read more